All clinical oncology research at UTSW is coordinated by the Clinical Protocol and Data Management Shared Resource (Clinical Research Office;CRO). The CRO, along with the Protocol Review and Monitoring Committee (PRMC) and Data and Safety Monitoring Committee (DSMC), is part of the Protocol Review and Monitoring System (PRMS), which has direct oversight over all clinical oncology research activities at UTSW and the Cancer Center, and is responsible for oversight of all patient-related cancer research. Dr. Joan Schiller, Deputy Director of the Cancer Center, serves as Medical Director of the CRO. Ms. Lynn Baker, MBA, Assistant Director for Clinical Research, is the administrative director. The CRO serves as the clinical coordinating center for all activities related to clinical cancer research at UTSW. It provides infrastructure for oversight, management, and monitoring of oncology clinical trials, thus facilitating high quality clinical research throughout our campus. Centralization of these activities ensures standardization of all aspects of clinical research, ensuring patient safety and coordination of clinical research activities. The resource also provides a central location for cancer protocols, an updated list of currently active studies, status reports of protocols, and quality control and training for clinical research personnel and junior investigators. The CRO also provides administrative support for the PRMS and DSMC, including timely submission of all protocols, amendments, and regulatory documents;monitoring and auditing of SCC protocols to ensure compliance with all regulations;and accurate and timely submission of data to regulatory bodies. It assesses and assists with resource allocation, and standardizes operational policies and procedures.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
1P30CA142543-01
Application #
8180826
Study Section
Subcommittee G - Education (NCI)
Project Start
2010-08-03
Project End
2015-07-31
Budget Start
2010-08-03
Budget End
2011-07-31
Support Year
1
Fiscal Year
2010
Total Cost
$105,280
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Singal, Amit G; Tiro, Jasmin A; Murphy, Caitlin C et al. (2018) Mailed Outreach Invitations Significantly Improve HCC Surveillance Rates in Patients With Cirrhosis: A Randomized Clinical Trial. Hepatology :
Ludlow, Andrew T; Wong, Mandy Sze; Robin, Jerome D et al. (2018) NOVA1 regulates hTERT splicing and cell growth in non-small cell lung cancer. Nat Commun 9:3112
Lewis, Joshua E; Costantini, Francesco; Mims, Jade et al. (2018) Genome-Scale Modeling of NADPH-Driven ?-Lapachone Sensitization in Head and Neck Squamous Cell Carcinoma. Antioxid Redox Signal 29:937-952
Rinkenberger, Nicholas; Schoggins, John W (2018) Mucolipin-2 Cation Channel Increases Trafficking Efficiency of Endocytosed Viruses. MBio 9:
Li, Xiangyi; Baek, GuemHee; Ramanand, Susmita G et al. (2018) BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer. Cell Rep 22:796-808
Li, Ran; Chiguru, Srinivas; Li, Li et al. (2018) Targeting Phosphatidylserine with Calcium-Dependent Protein-Drug Conjugates for the Treatment of Cancer. Mol Cancer Ther 17:169-182
Balasubramanian, Bijal A; Jetelina, Katelyn K; Bowen, Michael et al. (2018) Surveillance for colorectal cancer survivors in an integrated safety-net health system in the United States. Int J Care Coord 21:26-35
Rashdan, Sawsan; Minna, John D; Gerber, David E (2018) Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir Med 6:472-478
Wijayatunge, Ranjula; Holmstrom, Sam R; Foley, Samantha B et al. (2018) Deficiency of the Endocytic Protein Hip1 Leads to Decreased Gdpd3 Expression, Low Phosphocholine, and Kypholordosis. Mol Cell Biol 38:
Hamann, Heidi A; Shen, Megan J; Thomas, Anna J et al. (2018) Development and Preliminary Psychometric Evaluation of a Patient-Reported Outcome Measure for Lung Cancer Stigma: The Lung Cancer Stigma Inventory (LCSI). Stigma Health 3:195-203

Showing the most recent 10 out of 501 publications